Arca
Skip to content
Tools
Tools

Sphingosine 1-phosphate receptor

Family in Homo sapiens that 2 drugs act on.

  • Drugs that act on it: 2
  • Approved: 1
  • In phases 1 to 3: 1
  • Sponsors: 2
  • Genes: 5

Who is on it, and how far along

Every drug ChEMBL records acting on S1PR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 2

Approved1

  • Fingolimod

Phase 30

    Phase 21

    • Amiselimod

    Phase 10

      The landscape

      Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
      FingolimodApprovedNovartis PharmaceuticalsSmall moleculeAgonistSphingosine 1-phosphate receptor agonist16
      AmiselimodPhase 2Tanabe Pharma CorporationSmall moleculeModulatorSphingosine 1-phosphate receptor modulator0

      Open trials

      The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
      A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)FingolimodPhase 3Not yet recruitingBiogenMar 19, 2026
      Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple SclerosisFingolimodPhase 2 / Phase 3RecruitingTG Therapeutics, Inc.Oct 23, 2025
      Administration of Fingolimod in Greek Patients With Multiple Sclerosis.Fingolimod—Not yet recruitingElpen Pharmaceutical Co. Inc.Apr 29, 2025
      Phase 2 Study of Fingolimod in Lung CancersFingolimodPhase 2RecruitingMedical University of South CarolinaMay 21, 2024
      Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple SclerosisFingolimodPhase 3RecruitingBristol-Myers SquibbMay 10, 2024
      Montpellier PROspective Cohort in Relapsing Remitting Multiple Sclerosis Using Imaging and SerologicFingolimodNot applicableRecruitingUniversity Hospital, MontpellierJul 27, 2023
      A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their BabiesFingolimod—Active, not recruitingBiogenJan 18, 2023
      Demyelinating Diseases of the Central Nervous System Registry for Patients With Traditional Chinese Medicine (DATE-TCM)Fingolimod—Not yet recruitingDongzhimen Hospital, BeijingJun 13, 2022

      Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2363041, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. ChEMBL and Open Targets

      Esc

      Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

      Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.